Bozec A, Gros F-X, Penault-Llorca F, Patricia Formento, Anne Cayre, Clélia Dental, Marie-Christine Etienne-Grimaldi, Jean-Louis Fischel, Gérard Milano: Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer. 2008, 13: 1922-1930. 10.1016/j.ejca.2008.07.013.
Article
Google Scholar
Goon PK, Stanley MA, Ebmeyer J, Lars Steinsträsser, Tahwinder Upile, Waseem Jerjes, Manuel Bernal-Sprekelsen, Martin Görner, Holger H Sudhoff: HPV & head and neck cancer: a descriptive update. Head Neck Oncol. 2009, 1: 36-10.1186/1758-3284-1-36.
Article
PubMed Central
PubMed
Google Scholar
Segal NH, Saltz LB: Evolving treatment of advanced colon cancer. Annu Rev Med. 2009, 207-219. 10.1146/annurev.med.60.041807.132435.
Google Scholar
Iwase M, Takaoka S, Uchida M, Sayaka Yoshiba, Gen Kondo, Hitoshi Watanabe, Masaru Ohashi, Masao Nagumo: Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells. Oral Oncol. 2008, 4: 361-368. 10.1016/j.oraloncology.2007.04.006.
Article
Google Scholar
Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006, 17: 2666-2672. 10.1200/JCO.2005.04.8306.
Article
Google Scholar
Grandis JR, Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993, 15: 3579-3584.
Google Scholar
Hoang T, Huang S, Armstrong E, Jens C Eickhoff, Paul M Harari: Augmentation of radiation response with the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2006, 5: 1458-1465.
Article
Google Scholar
Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 8: 1935-1940.
Google Scholar
Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003, 14: 2787-2799. 10.1200/JCO.2003.01.504.
Article
Google Scholar
Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, Busse PM, Chan AW, Goguen LA, Norris CM, Annino DJ, Tishler RB: Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2009
Google Scholar
Giusti RM, Cohen MH, Keegan P, Pazdur R: FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Oncologist. 2009, 3: 284-290. 10.1634/theoncologist.2008-0254.
Article
Google Scholar
Bleeker WK, van Lammerts Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, van Dijk MA, Winkel van de JGJ, Parren PW: Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. 2004, 7: 4699-4707.
Article
Google Scholar
Egloff AM, Grandis JR: Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol. 2008, 3: 286-297. 10.1053/j.seminoncol.2008.03.008.
Article
Google Scholar
Rivera F, Salcedo M, Vega N, Blanco Y, López C: Current situation of zalutumumab. Expert Opin Biol Ther. 2009, 5: 667-674. 10.1517/14712590902932871.
Article
Google Scholar
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben R, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang K: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 6: 567-578. 10.1056/NEJMoa053422.
Article
Google Scholar
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang K: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2009
Google Scholar
Rivera F, García-Castaño A, Vega N, Vega-Villegas Maria E, Gutiérrez-Sanz L: Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther. 2009, 10: 1421-1428. 10.1586/era.09.113.
Article
Google Scholar
Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J: Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer. 2008, 12: 2710-2719. 10.1002/cncr.23442.
Article
Google Scholar
León X, Hitt R, Constenla M, Rocca A, Stupp R, Kovács AF, Amellal N, Bessa EH, Bourhis J: A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol). 2005, 6: 418-424.
Article
Google Scholar
Stewart JS, Cohen EE, Licitra L, van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake A, Swaisland A, Vokes EE: Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009, 11: 1864-1871. 10.1200/JCO.2008.17.0530.
Article
Google Scholar
Hegymegi-Barakonyi B, Eros D, Szántai-Kis C, Breza N, Bánhegyi P, Szabó Gábor V, Várkondi E, Peták I, Orfi L, Kéri G: Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR. Curr Opin Mol Ther. 2009, 3: 308-321.
Google Scholar
Seiwert TY, Cohen EE: Targeting angiogenesis in head and neck cancer. Semin Oncol. 2008, 3: 274-285. 10.1053/j.seminoncol.2008.03.005.
Article
Google Scholar
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993, 6423: 841-844. 10.1038/362841a0.
Article
Google Scholar
Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009, 3: 247-257. 10.1016/S1470-2045(09)70002-6.
Article
Google Scholar
Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, Wilkie D, Petrenciuc O, Chen EX: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007, 24: 3766-3773. 10.1200/JCO.2006.10.2871.
Article
Google Scholar
Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, Grandis Jennifer R: SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res. 2004, 17: 6166-6173. 10.1158/0008-5472.CAN-04-0504.
Article
Google Scholar
Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM: Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther. 2009, 8: 696-703.
Article
PubMed Central
CAS
PubMed
Google Scholar
Johnson FM, Saigal B, Talpaz M, Donato NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res. 2005, 19 (Pt 1): 6924-6932. 10.1158/1078-0432.CCR-05-0757.
Article
Google Scholar
Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, Shyr Y, Parker J, Gilbert J, Murphy BA: Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2009
Google Scholar
Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW, Kumar P: Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer. 2009, 9: 1379-1384. 10.1038/sj.bjc.6605043.
Article
Google Scholar